• Earlier this month, Neurocrine Biosciences reported first-quarter 2026 revenue of US$814.5 million and net income of US$197.9 million, and published the first peer-reviewed expert algorithms for glucocorticoid dose reduction in classic congenital adrenal hyperplasia patients treated with CRENESSITY.
• These new, age-specific treatment algorithms and real-world functional data for INGREZZA deepen clinical confidence in Neurocrine’s therapies for complex neurological and endocrine disorders.
• We’ll now examine how these expert CRENESSITY dosing recommendations shape Neurocrine’s investment narrative, particularly its endocrinology growth and product durability.

Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

Neurocrine Biosciences Investment Narrative Recap

To own Neurocrine, you need to believe its core neurology and endocrinology franchises, led by INGREZZA and CRENESSITY, can sustain meaningful demand despite pricing and reimbursement headwinds. The new CRENESSITY dosing algorithms likely support the short term catalyst of continued endocrinology uptake, but they do not remove the key risk of portfolio concentration and payer pressure if pricing or access terms worsen.

Among recent updates, the US$814.5 million first quarter 2026 revenue and US$197.9 million net income stand out, because they frame how much current performance relies on INGREZZA while CRENESSITY and the Soleno acquisition are still scaling. Together with the new CAH dosing recommendations, they highlight both the opportunity for broader endocrine growth and the exposure if payers push back on reimbursement for these growing therapies.

Yet behind Neurocrine’s solid CAH progress, investors should also be aware that concentrated reliance on a few flagship drugs leaves the company more exposed if...

Neurocrine Biosciences' narrative projects $4.1 billion revenue and $1.0 billion earnings by 2029. This requires 13.0% yearly revenue growth and roughly a $521 million earnings increase from $478.6 million today.

Uncover how Neurocrine Biosciences' forecasts yield a $186.45 fair value, a 21% upside to its current price.

Exploring Other Perspectives

While consensus focuses on growth from INGREZZA and CRENESSITY, the most bearish analysts saw only about US$3.8 billion revenue and US$641.7 million earnings by 2029, reminding you that views on payer risk and long term pricing pressure can differ sharply and may shift again after the new CRENESSITY data.

Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 54 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.